Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO

Abstract The BRCAPRO model estimates carrier probabilities for the BRCA1 and BRCA2 genes, and was recently enhanced to use estrogen receptor (ER) and progesterone receptor (PR) status of breast cancer. No independent assessment of the added value of these markers exists. Moreover, earlier versions of BRCAPRO did not use human epidermal growth factor receptor 2 (Her-2/neu) status of breast cancer. Here, we incorporate Her-2/neu in BRCAPRO and validate all the markers. We trained the enhanced model on 406 germline tested individuals, and validated on a separate clinical cohort of 796 individuals for whom test results and family history are available. For model-building, we estimated joint probabilities of ER, PR, and Her-2/neu status for carriers and non-carriers of BRCA1/2 mutations. For validation, we obtained BRCAPRO predictions with and without markers. We calculated area under the receiver operating characteristic curve (AUC), sensitivity, specificity, predictive values, and correct reclassification rates. The AUC for predicting BRCA1 status among individuals who are carriers of at least one mutation improved when ER and PR were used. The AUC for predicting the presence of either mutation improved when Her-2/neu was added. Use of markers also produced highly significant correct reclassification improvements in both cases. Breast tumor markers are useful for prediction of BRCA1/2 mutation status. ER and PR improve discrimination between BRCA1 and BRCA2 mutation carriers while Her-2/neu helps discriminate between carriers and non-carriers, particularly among women who are ER positive and Her-2/neu negative. These results support the use of the enhanced version of BRCAPRO in clinical settings.

[1]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[2]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[3]  G Parmigiani,et al.  Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations , 2004, Journal of Medical Genetics.

[4]  B. Mukesh,et al.  Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Robert Tibshirani,et al.  An Introduction to the Bootstrap , 1994 .

[6]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[7]  G. Mills,et al.  Assessing BRCA carrier probabilities in extended families. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Parmigiani,et al.  Multiple diseases in carrier probability estimation: Accounting for surviving all cancers other than breast and ovary in BRCAPRO , 2008, Statistics in medicine.

[9]  Karl W Broman,et al.  BayesMendel: an R Environment for Mendelian Risk Prediction , 2004, Statistical applications in genetics and molecular biology.

[10]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[11]  G. Parmigiani,et al.  Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction , 2008, Breast Cancer Research.

[12]  J. Dowty,et al.  Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models , 2007, Familial Cancer.

[13]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[14]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[15]  G. Parmigiani,et al.  Tailoring BRCAPRO to Asian-Americans. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Rebbeck,et al.  Incorporating tumour pathology information into breast cancer risk prediction algorithms , 2010, Breast Cancer Research.

[17]  J. Kirk,et al.  Evaluation of models to predict BRCA germline mutations , 2006, British Journal of Cancer.

[18]  Holly Neibergs,et al.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 , 2004 .

[19]  Nancy R Cook,et al.  The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women , 2006, Annals of Internal Medicine.

[20]  Validity of Models for Predicting BRCA1 and BRCA2 Mutations , 2007, Annals of Internal Medicine.

[21]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Eric R. Ziegel,et al.  Modeling in Medical Decision Making , 2002, Technometrics.

[23]  L. Guarente,et al.  Increased Life Span due to Calorie Restriction in Respiratory-Deficient Yeast , 2006, PLoS genetics.

[24]  Christopher I Amos,et al.  Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Gordon B Mills,et al.  Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. , 2002, Journal of the National Cancer Institute.